Clinical Trial Update: A Phase I, Autologous ex Vivo Expanded and Activated NK Cell, Magicell-NK, Infusion for Colon Cancer Post Resection Study [Phase 1]

View source ↗

Summary

A Phase I study evaluating autologous ex vivo expanded and activated NK cell therapy (Magicell-NK) after surgical resection for colon cancer. Recruitment is ong…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer

Drugs mentioned

• Magicell-NK (Autologous ex vivo expanded and activated natural killer cells)

Snippet

Sponsor: Medigen Biotechnology Corporation | Conditions: Colon Cancer Stage I | Phase 1 | Status: RECRUITING